Latest Breaking News On - Sankyo group - Page 1 : comparemela.com
The following discussion and analysis of our financial condition and results of
operations should be read in conjunction with our condensed consolidated
financial statements and related notes. | May 9, 2023
/PRNewswire/ American Regent, Inc. is pleased to announce the launch of Selenious Acid Injection, USP in a new concentration and vial size. The Selenious.
(0)
Large routine clinical practice study, ETNA-AF-Europe, demonstrates continued benefits of edoxaban across age groups and supports treatment in elderly patient populations, in line with those observed in ETNA-AF after one year and in ENGAGE AF-TIMI 48
ETNA-AF-Europe is part of the global ETNA-AF programme, which is the largest prospective, non-interventional study investigating a single non-vitamin K antagonist oral anticoagulant (NOAC) to date
Data presented at the annual scientific meeting of the European Heart Rhythm Association
Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced the presentation of new routine clinical practice outcomes data confirming, in line with the randomised clinical trial data, the consistent effectiveness and safety profile of LIXIANA
New two-years follow-up data from ETNA-AF-Europe reaffirms benefit of LIXIANA® (edoxaban) in people with atrial fibrillation
04/26/2021 | 03:01am EDT
Send by mail :
Message :
Required fields
Large routine clinical practice study, ETNA-AF-Europe, demonstrates continued benefits of edoxaban across age groups and supports treatment in elderly patient populations, in line with those observed in ETNA-AF after one year and in ENGAGE AF-TIMI 48
ETNA-AF-Europe is part of the global ETNA-AF programme, which is the largest prospective, non-interventional study investigating a single non-vitamin K antagonist oral anticoagulant (NOAC) to date
Data presented at the annual scientific meeting of the European Heart Rhythm Association
Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced the presentation of new routine clinical practice outcomes data confirming, in line with the randomised clinical trial data, the consistent effectiveness and safety profile of LIXIANA
Daiichi Sankyo UK, Limited: ENHERTU - (TRASTUZUMAB DERUXTECAN) NOW AVAILABLE VIA THE CANCER DRUGS FUND FOR THE TREATMENT OF HER2 POSITIVE METASTATIC BREAST CANCER
Reimbursement decisions in Scotland, Wales, and Northern Ireland to be announced later this year
Daiichi Sankyo UK, Limited
(hereafter, Daiichi Sankyo) and AstraZeneca UK today welcome the news that the National Institute for Health and Care Excellence (NICE) has recommended Enhertu (trastuzumab deruxtecan) for use within the Cancer Drugs Fund (CDF) as an option for treating HER2 positive unresectable or metastatic breast cancer in adults who have received two or more prior anti-HER2 based therapies.
In the UK, almost 54,000 cases of breast cancer in women are diagnosed annually, with an estimated one in five cases being HER2 positive.